Furthermore, hip arthritis and sacroiliitis often prove resistant to TNF inhibitor therapy, highlighting a potential limitation in the ability of these agents to prevent disease progression in these specific locations [13]. The gene discussed is TNF; the disease is Sacroiliac arthritis.